<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295176</url>
  </required_header>
  <id_info>
    <org_study_id>ARMP-11</org_study_id>
    <nct_id>NCT02295176</nct_id>
  </id_info>
  <brief_title>Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic Syndrome</brief_title>
  <acronym>ARMP-11</acronym>
  <official_title>Metabolic and Cardiovascular Effects of a Proprietary Nutraceutical Containing Berberine, Policosanols and Red Yeast in Subjects With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rottapharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rottapharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to evaluate the effects of Armolipid Plus on insulin sensitivity in&#xD;
      patients with MetS and increased LV mass.&#xD;
&#xD;
      168 patients will be enrolled in this randomized, double-blind, parallel-group,&#xD;
      placebo-controlled trial and treated for 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic syndrome (MetS) is a highly prevalent condition characterized by visceral obesity,&#xD;
      abnormalities of glucidic and lipid metabolism, and increased risk for cardiovascular events.&#xD;
      Such findings appear to be associated with a decrease in insulin sensitivity. Management of&#xD;
      metabolic syndrome is currently aimed at treating individual components of the disease&#xD;
      without addressing this underlying pathophysiologic mechanism; this translates into multidrug&#xD;
      regimens, high costs and patient compliance issues.&#xD;
&#xD;
      A complication of hypertension is hypertrophy of the left ventricle (LV), which is closely&#xD;
      related to the incidence of cardiovascular events whose regression results in a proportional&#xD;
      reduction of the risk. But also other factors contribute as sex, age, race, genetics, diet&#xD;
      and insulin resistance.&#xD;
&#xD;
      MetS is closely related to hypertrophy of the LV. Therefore it is possible that the treatment&#xD;
      of MetS may be an effective strategy for the prevention of organ damage.&#xD;
&#xD;
      Armolipid Plus (an association of berberine 500mg, red yeast rice titled in 3 mg monacolin&#xD;
      K,- policosanol 10 mg, coenzyme Q10 2mg,astaxanthin 0,5mg, folic acid 0,2mg) has been found&#xD;
      to be effective at reducing blood cholesterol and triglycerides, and at improving endothelial&#xD;
      function; subgroup analyses also suggested a benefit on glucose metabolism, myocardial mass&#xD;
      and improved diastolic function in subjects with MetS and early organ damage.&#xD;
&#xD;
      Aim of the study is to evaluate the effects of Armolipid Plus on insulin sensitivity in&#xD;
      patients with MetS and increased LV mass.&#xD;
&#xD;
      168 patients will be enrolled in this randomized, double-blind, parallel-group,&#xD;
      placebo-controlled trial; active treatment will consist of Armolipid Plus (1 tbl qd).&#xD;
&#xD;
      Primary end point will be the reduction of the insulin resistance in patients with metabolic&#xD;
      syndrome and increased LV mass.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome measure will be the reduction of the insulin/glucose ratio, both after overnight fast (HOMA index)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac remodeling assessed by echocardiogram, lipid profile, subtypes of LDL, blood pressure, and high-sensitivity C-reactive protein.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin-resistance</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Armolipid Plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Armolipid Plus: 1 tablet daily in the evening after dinner for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet matching Armolipid Plus daily in the evening after dinner for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Armolipid Plus</intervention_name>
    <arm_group_label>Armolipid Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male and Female 18-70 aged, with diagnosis of metabolic syndrome, defined by the&#xD;
             presence of waist circumference &gt;102 cm (♂) or &gt;88 cm(♀), and two or more of these&#xD;
             criteria:&#xD;
&#xD;
               -  fasting blood glucose &gt;100 mg&#xD;
&#xD;
               -  systolic blood pressure &gt;135 or diastolic blood pressure &gt;85 mmHg or patients in&#xD;
                  treatment with antihypertensive drugs&#xD;
&#xD;
               -  triglyceridemia &gt;150 mg/dl&#xD;
&#xD;
               -  HDL cholesterolemia &lt; 40 mg/dl(M), &lt; 50 mg/dl(F).&#xD;
&#xD;
          -  left ventricular hypertrophy: left ventricular mass indexed to height &gt;44 g/m2,7(♀)or&#xD;
             &gt;48 g/m2(♂).&#xD;
&#xD;
          -  antihypertensive and lipid-lowering therapy (if applicaple) stable for at least three&#xD;
             months.&#xD;
&#xD;
          -  ability to understand and sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or lactation period&#xD;
&#xD;
          -  diabetes mellitus or pharmacological treatment for this condition&#xD;
&#xD;
          -  hepatic failure&#xD;
&#xD;
          -  creatininemia &gt;2mg/dl&#xD;
&#xD;
          -  triglyceridemia &gt;500mg/dl&#xD;
&#xD;
          -  severe obesity (BMI &gt;35)&#xD;
&#xD;
          -  chronic renal failure with glomerular filtration rate &lt;30ml/min&#xD;
&#xD;
          -  triglycerides &gt;500mg/dl&#xD;
&#xD;
          -  left ventricular systolic dysfunction (LVEF &lt;40%)&#xD;
&#xD;
          -  hypertrophic cardiomyopathy&#xD;
&#xD;
          -  valvular stenosis&#xD;
&#xD;
          -  previous myocardial infarction with acinesie&#xD;
&#xD;
          -  intermediate or severe cardiac valve disorders&#xD;
&#xD;
          -  intolerance to any components of Armolipid Plus&#xD;
&#xD;
          -  pacemaker generated arrhythmia&#xD;
&#xD;
          -  Inadequately controlled high blood pressure during therapy optimization (SBP &gt;140mmHg&#xD;
             or DBP &gt;90mmHg)&#xD;
&#xD;
          -  patients with comorbidities are allowed (e.g. ischemic heart disease, dysthyroidism)&#xD;
             but they have got to be in stable therapy for at least 3 months and they did not have&#xD;
             major clinical events in the last three months;&#xD;
&#xD;
          -  heart failure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Domenico Bonaduce</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ferruccio Galletti</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giuseppe Schillaci</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

